Vical Licenses Vaxfectin(R) Adjuvant to Cyvax for Use in Malaria Vaccines

[at noodls] – SAN DIEGO, Dec. 5, 2012 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) announced today a worldwide, nonexclusive license of its patented Vaxfectin® adjuvant to Cyvax, Inc., a privately held vaccine … more

View todays social media effects on VICL

View the latest stocks trending across Twitter. Click to view dashboard

See who Vical is hiring next, click here to view